Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

Press bodies have expressed concern about the recently-notified Digital Personal Data Protection Rules, 2025, saying that the “ambiguous obligations” they impose could open the door for indirect ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on knowledge of ...

The key is to balance offense and defense. by Leandro DalleMule and Thomas H. Davenport More than ever, the ability to manage torrents of data is critical to a company’s success. But even with the ...

Australia's NEXTDC inks MoU with OpenAI to develop AI infrastructure in Sydney, shares jump NEXTDC Ltd said on Friday it inked a memorandum of understanding with ChatGPT maker OpenAI to collaborate on ...